ArticleFrontiers in oncology2020

Metastatic Breast Cancer Coexisting With HER-2 Amplification and EGFR Exon 19 Deletion Benefits From EGFR-TKI Therapy: A Case Report.

Wei Jing et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.